The New England journal of medicine2014Vol. 371pp. -
250
l2014thelenalidomide
Abstract
As compared with MPT, continuous lenalidomide-dexamethasone given until disease progression was associated with a significant improvement in progression-free survival, with an overall survival benefit at the interim analysis, among patients with newly diagnosed multiple myeloma who were ineligible f …